GBT to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 23, 2022

Rhea-AI Summary

Global Blood Therapeutics (GBT) will release its Q4 and full year 2021 financial results on February 23, 2022, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results and provide a general business update. Interested parties can join the call at 877-407-3982 (domestic) or +1 201-493-6780 (international). Additionally, GBT focuses on treating sickle cell disease (SCD) and is advancing its pipeline, including the FDA-approved drug Oxbryta and other candidates.

Positive

• Focus on sickle cell disease with FDA-approved Oxbryta.
• Pipeline includes promising drugs in development, such as inclacumab and GBT021601.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2021 financial results on Wednesday, February 23, 2022, after U.S. financial markets close.

Management will host a conference call on Wednesday, February 23, 2022, at 4:30 p.m. ET to discuss fourth quarter and full year 2021 financial results and to provide a general business update. To participate in the conference call, please dial 877-407-3982 (domestic) or +1 201-493-6780 (international). A live audio webcast can be accessed on GBT’s website at www.gbt.com in the Investors section. The archived audio webcast will be available for one month following the event.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com

Courtney Roberts (investors)
650-351-7881
croberts@gbt.com

FAQ

When will GBT announce its financial results for 2021?

GBT will announce its financial results on February 23, 2022.

What time is GBT's conference call for financial results?

The conference call will take place at 4:30 p.m. ET on February 23, 2022.

How can I access GBT's financial results conference call?

You can join the conference call by dialing 877-407-3982 domestically or +1 201-493-6780 internationally.

What is GBT's focus area in biopharmaceuticals?

GBT is focused on the discovery and development of treatments for sickle cell disease.

What medications has GBT developed for sickle cell disease?

GBT has developed Oxbryta (voxelotor) and is advancing other treatments like inclacumab.